Reuters -- A trial of Amgen Inc's Aranesp found the blockbuster anemia drug does not have a significant effect on the risk of heart attack and other cardiac events in kidney patients, the company said on Tuesday.
Reuters -- A trial of Amgen Inc's Aranesp found the blockbuster anemia drug does not have a significant effect on the risk of heart attack and other cardiac events in kidney patients, the company said on Tuesday.
